JPRN-UMIN000031867已完成未知
The Effect of SGLT2 inhibitor Tofogliflozin to Quality of Life of Patients with Type 2 Diabetes Mellitus Research - The Effect of SGLT2 inhibitor Tofogliflozin to Quality of Life of Patients with Type 2 Diabetes Mellitus Research (SGITR study)
HO Kyoto Medical Center, Diabetes Center0 个研究点目标入组 30 人开始时间: 2018年3月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients using pharmaceuticals to treat diabetes mellitus other than DPP-4 inhibitor and sulfonyl urea and insulin (including GLP-1 receptor agonist) for 3 month or more prior to the moment starting tofogliflozin. 2) Patients with the serum creatinine levels of 2.0 mg/dl or more. 3) Patients with hypothyroidism. 4) Patients with hyperthyroidism. 5) Patients with BMI less than 18.5 kg/m2, or 40 kg/m2 or more. 6) Patients who have allergy to tofogliflozin. 7) Patients with severe ketosiss, diabetic coma or impending diabetic coma. 8) Patinets with severe infection, in perioperative period, or with severe trauma. 9) Patients to whom participating this study is considered to be inappropriate for any reason.
研究者
相似试验
招募中
不适用
The effect of SGLT2 inhibitor tofogliflozin on glycemic daily variation by blood glucose using CGMs in patient with type 2 diabetes.JPRN-UMIN000025454Dokkyo Medical University Department of Endocrinology and Metabolism20
已完成
2 期
Effect of the SGLT-2 inhibitor dapagliflozine on impaired awareness of hypoglycemia in type 1 diabetesImpaired Awareness of Hypoglycemiahypoglycemia unawareness10018424DiabetesNL-OMON48616Radboud Universitair Medisch Centrum15
进行中（未招募）
1 期
To investigate whether treatment with the SGLT-2 inhibitor dapagliflozin improves the perception of hypoglycemia in people with type 1 diabetes with impaired awareness of hypoglycemiaType 1 diabetesEUCTR2018-001569-17-NLRadboud university medical center15
已完成
不适用
Effects of tofogliflozin treatment on suppression of nocturia and promotion of urinary sodium excretion.JPRN-UMIN000048030Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine36
已完成
不适用
Effect of SGLT2 inhibitor, canagliflozin, for the size of lipid particlesType 2 diabetesJPRN-UMIN000020027Tokyo Medical and Dental University Department of Medical Genetics / Gerontorgy30